Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research report released on Wednesday morning. The firm currently has $48.00 target price on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Several other equities analysts have also issued reports on CTLT. ValuEngine lowered Catalent from a buy rating to a hold rating in a research report on Monday, October 2nd. Needham & Company LLC restated a hold rating on shares of Catalent in a research report on Monday, October 23rd. Wells Fargo & Co raised their price target on Catalent from $39.00 to $43.00 and gave the stock an outperform rating in a research report on Wednesday, September 20th. First Analysis assumed coverage on Catalent in a research report on Friday, January 5th. They set an equal weight rating on the stock. Finally, Bank of America restated a buy rating and set a $45.00 price target (up from $40.00) on shares of Catalent in a research report on Wednesday, September 20th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $44.44.
Catalent (NYSE:CTLT) opened at $42.94 on Wednesday. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $5,704.96, a PE ratio of 49.36, a PEG ratio of 2.73 and a beta of 1.41. Catalent has a 1 year low of $25.72 and a 1 year high of $43.42.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same period last year, the company earned $0.16 EPS. Catalent’s revenue for the quarter was up 23.0% compared to the same quarter last year. sell-side analysts anticipate that Catalent will post 1.47 earnings per share for the current fiscal year.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were purchased at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Catalent by 15.2% in the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Catalent by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock worth $355,192,000 after buying an additional 369,526 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Catalent in the 2nd quarter worth approximately $239,629,000. State Street Corp grew its position in shares of Catalent by 10.7% in the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after buying an additional 418,196 shares during the last quarter. Finally, Earnest Partners LLC grew its position in shares of Catalent by 0.5% in the 3rd quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after buying an additional 12,652 shares during the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.